Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Predicted Market Size and CAGR of the Anti-Inflammatory Biologics Market by the End of the 2029?
The anti-inflammatory biologics market size has grown strongly in recent years. It will grow from $108.11 billion in 2024 to $118.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising prevalence of arthritis, increasing awareness of autoimmune diseases, growing introduction of new biologics, increasing healthcare infrastructure, and rising regulatory approvals.
The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $166.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing adoption of biologics, rising demand for targeted therapies, increasing patient preference for long-term remission, increasing use of biomarkers for disease monitoring, and growing demand for personalized medicine. Major trends in the forecast period include advancements in biologic drug development, developing oral biologics for inflammation, technology-driven drug delivery systems, developments in biosimilars, and advancements in diagnostic tools.
Get your free report sample today:
What Are the Significant Market Forces Driving the Anti-Inflammatory Biologics Market Performance?
The rising prevalence of arthritis is expected to propel the growth of the anti-inflammatory biologics market going forward. Arthritis refers to inflammation or swelling of one or more joints, causing pain, stiffness, and reduced movement, often worsening with age. The rising prevalence of arthritis is primarily due to increasing obesity rates, as excess body weight places additional stress on joints, leading to inflammation and joint degeneration. Anti-inflammatory biologics are useful for arthritis by targeting specific components of the immune system to reduce inflammation, slow joint damage, relieve symptoms, and improve physical function and quality of life for people with moderate to severe arthritis. For instance, in March 2023, according to the Office for Health Improvement and Disparities, a UK-based government department, in 2022, 17.6% of people aged 16 and over had a long-term MSK condition such as arthritis or an ongoing back or joint problem, up from 17.0% in 2021. Therefore, the rising prevalence of arthritis is driving the growth of the anti-inflammatory biologics market.
Which Segments Are Likely to Shape the Future Outlook of the Anti-Inflammatory Biologics Market?
The anti-inflammatory biologics market covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Phosphodiesterase-4 Inhibitors, Sphingosine 1-Phosphate Receptor Modulators, Anti-IgE And Other Biologics
Which Major Trends Are Expected to Define the Anti-Inflammatory Biologics Market Through 2029?
Major companies operating in the anti-inflammatory biologics market are focusing on developing innovative solutions, such as interleukin-6 (IL-6) receptor antagonists, to target chronic inflammatory diseases with greater specificity and reduced side effects. Interleukin-6 (IL-6) receptor antagonists are biologic drugs that block the IL-6 receptor to reduce inflammation and immune response in conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the US Food and Drug Administration (FDA) for Kevzara as the first and only biologic treatment indicated for patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor, helping to reduce inflammation linked to PMR, a condition that causes muscle pain and stiffness, mainly in older adults. Unlike traditional steroids, which carry risks such as osteoporosis and diabetes with prolonged use, Kevzara provides a more targeted, steroid-sparing approach that supports improved patient outcomes and enhanced long-term safety.
Which Major Organizations Influence the Direction of the Anti-Inflammatory Biologics Market?
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, Hansa Biopharma AB.
Get the detailed anti-inflammatory biologics market report today
Which Region Holds the Largest Share of the Anti-Inflammatory Biologics Market?
North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment